Corcept Therapeutics Incorporated (CORT)

NCM – Real Time Price. Currency in USD

112.67

+0.81 (0.72%)

Market open: Aug 12, 2026, 10:39 AM EDT

113.08

+1.23 (1.10%)

Previous after-hours: Aug 11, 2026, 7:42 PM EDT

Stock details

Previous close: 111.86$
Day's range: 111.66 - 114.71$
52-week range: 28.66 - 122.21$
Volume: 699 950
Average volume: 1 517 838
Beta: 1.19
EPS (TTM): 0.52
PE ratio (TTM): 267.16
Forward P/E: 55.24
Market cap: 12 091 886 676
Shares outstanding: 108 098 397
Dividend yield: N/A
Next earnings date: 2026-11-04
Sector: Healthcare
Industry: Biotechnology

About the company

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose... read more

CEO: Joseph Belanoff
Country: United States
IPO Date
Employees: 730
Fiscal Year End: January - December
Website: https://www.corcept.com

Revenue Breakdown

Pharmaceutical Products / 100.00%

News

No Data

There are no news for this stock.

Chart: CORT

Loading Chart...

Overall Score

5.7 / 1057%

Octagon View

Strength & Weakness

Company's cash reserves $111.0M significantly exceed its total debt $9.4M, ensuring strong financial flexibility

Total current assets $435.3M exceed Total current liabilities $153.8M, highlighting excellent liquidity

Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management

The company has no interest-bearing debt, showcasing excellent financial strength

The company generates positive free cash flow $31.0M, supporting its financial health

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	2.83	6.05	10
Quick ratio	2.74	5.63	10
Debt to Equity	0.01	0.30	9.0
Debt to Assets	0.01	1.04	9.0
Interest coverage	N/A	-16.91	10
Weighted average score			9.6

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	402M	482M	675M	761M	831M
Gross Profit	396M	476M	664M	748M	817M
Operating Income	113M	107M	137M	45M	6M
Net Income	101M	105M	140M	98M	54M
EBITDA	116M	108M	138M	47M	9M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	98.41	-11.73	10
Operating margin %	16.12	-24.60	8.0
Net margin %	16.45	-172.20	10
EBITDA margin %	16.46	-201.27	6.0
Cash flow margin %	13.10	-156.39	6.0
Weighted average score			8.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	9.19	-57.97	8.0
ROE	11.60	-63.56	7.0
ROIC	11.50	-42.57	7.0
ROCE	0.10	-71.10	2.0
Weighted average score			6.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	49.44	305.01	10
Next quarter	81.03	392.47	10
Current year	42.22	146.95	10
Next year	41.05	85.37	10
Weighted average score			10

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	55.33	235.06	220	282.73	10
Y/Y	31.74	21.76	24.14	-29.31	7.8
3y average	24.26	2.29	1.86	10.89	5.8
5y average	17.2	0.61	1.61	3.08	4.5
Weighted average score					7.0

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	253.84	-5.25	2.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	16.23	64.66	6.4
P/B	17.50	2.96	2.8
Weighted average score			3.1

DCF Model

DCF Model Period5 years

Discount rate8.5%

Perpetual growth rate3%

Revenue 5 year CAGR25.92%

FCF 5 year CAGR4

Fair value125.7$

Stock price111.66$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$125.7

UndervaluedStock priceOvervalued

$111.66

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Joseph Belanoff

Country

United States

IPO Date

Employees

730

Fiscal Year End

January - December

Website

https://www.corcept.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

2.83

6.05

Quick ratio

2.74

5.63

Debt to Equity

0.01

0.30

9.0

Debt to Assets

0.01

1.04

9.0

Interest coverage

N/A

-16.91

Weighted average score

9.6

METRIC

2022

2023

2024

2025

TTM

Total Revenue

402M

482M

675M

761M

831M

Gross Profit

396M

476M

664M

748M

817M

Operating Income

113M

107M

137M

45M

Net Income

101M

105M

140M

98M

54M

EBITDA

116M

108M

138M

47M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

98.41

-11.73

Operating margin %

16.12

-24.60

8.0

Net margin %

16.45

-172.20

EBITDA margin %

16.46

-201.27

6.0

Cash flow margin %

13.10

-156.39

6.0

Weighted average score

8.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

9.19

-57.97

8.0

ROE

11.60

-63.56

7.0

ROIC

11.50

-42.57

7.0

ROCE

0.10

-71.10

2.0

Weighted average score

6.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

49.44

305.01

Next quarter

81.03

392.47

Current year

42.22

146.95

Next year

41.05

85.37

Weighted average score

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

55.33

235.06

220

282.73

Y/Y

31.74

21.76

24.14

-29.31

7.8

3y average

24.26

2.29

1.86

10.89

5.8

5y average

17.2

0.61

1.61

3.08

4.5

Weighted average score

7.0

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

253.84

-5.25

2.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

16.23

64.66

6.4

P/B

17.50

2.96

2.8

Weighted average score

3.1

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Corcept Therapeutics Incorporated (CORT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Corcept Therapeutics Incorporated (CORT)

Stock details

About the company

Revenue Breakdown

News

Chart: CORT

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$125.7

$111.66

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: CORT

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$125.7

$111.66

Economic Moat